In silico drug repurposing in COVID-19: A network-based analysis - 18/09/21
Abstract |
The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repurposing represents a faster and cheaper method than de novo drug discovery. In this study, we examined three different network-based approaches to identify potentially repurposable drugs to treat COVID-19. We analyzed transcriptomic data from whole blood cells of patients with COVID-19 and 21 other related conditions, as compared with those of healthy subjects. In addition to conventionally used drugs (e.g., anticoagulants, antihistaminics, anti-TNFα antibodies, corticosteroids), unconventional candidate compounds, such as SCN5A inhibitors and drugs active in the central nervous system, were identified. Clinical judgment and validation through clinical trials are always mandatory before use of the identified drugs in a clinical setting.
Il testo completo di questo articolo è disponibile in PDF.Graphical Abstract |
Highlights |
• | Drug repurposing based on network medicine approach identified new drugs for COVID-19. |
• | SAveRUNNER identified drugs acting on targets within or next to COVID-19 module. |
• | Network-based separation measure found disease modules close to COVID-19 module. |
• | Random walk with restart identified diseases whose drugs may perturb the COVID-19 module. |
• | Interesting identified drugs are active in the CNS and other are antiarrhythmic agents. |
Keywords : COVID-19, Drug repurposing, Corticosteroid, Heparin, Inflammatory bowel disease, Septic shock
Mappa
Vol 142
Articolo 111954- Ottobre 2021 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.